PROFESSOR SCOTT MENZIES is Professor in the Discipline of Dermatology at The University of Sydney and is currently Deputy Director of the Sydney Melanoma Diagnostic Centre at the Royal Prince Alfred Hospital (previously Director from 2003-2013). He is a recognised world leader in the development of technologies for the diagnosis of primary melanoma of the skin including dermoscopy, sequential digital dermoscopy imaging, in-vivo confocal microscopy, and automated diagnostic techniques.
Contribution to field of research
He continues to be a world leader in the development of technologies for the diagnosis of primary melanoma of the skin (dermoscopy, sequential digital dermoscopy imaging, in-vivo confocal microscopy, and automated diagnostic techniques) - work that has directly resulted in category A recommendations for the diagnosis of melanoma in NH&MRC-ratified national guidelines, and successfully bringing diagnostic techniques to market. In the last 5 years he led a prospective trial of a high-risk melanoma cohort that assessed the relative efficacy of melanoma diagnostic methods. This included a separate cost analysis and development of a psycho-educational intervention for the management of patients with a high risk for developing primary melanoma. This protocol subsequently received funding for a roll-out assessment of both the diagnostic and psychological interventions in multiple centres in NSW. He also led an international study describing the dermoscopy diagnosis of the world’s largest series of nodular melanoma and is a member of the team that has published the world’s largest series for the diagnosis of melanoma (both lentigo maligna and invasive melanoma) using in-vivo confocal microscopy. He also led the world’s largest study that describes the variables predicting morphological change of naevi over time using sequential digital dermoscopy imaging (and has previously published the world’s largest series of short-term sequential digital dermoscopy imaging of melanocytic lesions). He is currently on the scientific advisory board of an international company who is developing automated diagnostic devices for primary melanoma (SciBase AB, Sweden).